secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-275889
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Q3 net loss $35.7M; pauses solid tumor enrollment, advances heme pivotal trial
--------------------------------------------------------------------------------

- Revenue $2.5M (up from $1.0M YoY); net loss $35.7M vs $29.9M; cash $184.5M funds into H2 2027.
- FDA agreed on pivotal trial design for TSC-101 in AML/MDS; pivotal launch expected Q2 2026.
- Strategic decision: prioritize heme program, pause PLEXI-T solid tumor enrollment; shift to in vivo engineering.
- Plans to present updated ALLOHA heme data at ASH Dec 2025; two IND submissions for heme candidates in Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312525275889/0001193125-25-275889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312525275889/tcrx-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-275889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer